Retraction Note: Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia (Cancer Gene Therapy, (2015), 22, 12, (573-580), 10.1038/cgt.2015.50);Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia

Cancer Gene Therapy

Volumn 22, Issue 12, 2015, Pages 573-580

  Zhu, X ^a   Zhao, H ^b   Lin, Z ^c   Zhang, G ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BCR ABL PROTEIN; COMPLEMENTARY DNA; MICRORNA; MICRORNA 130A; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ATM PROTEIN, HUMAN; MIRN130 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DRUG SENSITIZATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA EXTRACTION; WESTERN BLOTTING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945152229     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/s41417-022-00573-z     Document Type: Erratum

References (45)

1. Cai J, Wu G, Tan X, Han Y, Chen C, Li C et al. Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. PLoS One 2014; 9: e105200.
2. Joshi D, Chandrakala S, Korgaonkar S, Ghosh K, Vundinti BR. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene 2014; 542: 109-112.
3. Nishioka C, Ikezoe T, Yang J, Nobumoto A, Tsuda M, Yokoyama A. Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci 2014; 105: 297-307.
4. Karimiani EG, Marriage F, Merritt AJ, Burthem J, Byers RJ, Day PJ. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein. Exp Hematol 2014; 42: 183-191, e5.
5. Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M et al. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res 2013; 37: 1278-1286.
6. Hamerschlak N, Souza CD, Cornacchioni AL, Pasquini R, Tabak D, Spector N et al. Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients. Sao Paulo Med J 2014; 65: 276-283.
7. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K et al. Increased serum levels of circulating exosomal microRNA-373 in receptornegative breast cancer patients. Oncotarget 2014; 5: 9650-9663.
8. Zhang M, Luo W, Huang B, Liu Z, Sun L, Zhang Q et al. Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression. PLoS One 2013; 8: e79173.
9. Xishan Z, Xianjun L, Ziying L, Guangxin C, Gang L. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia. Cancer Gene Ther 2014; 21: 397-404.
10. Zhang J, Wang P, Zhu J, Wang W, Yin J, Zhang C et al. SPARC expression is negatively correlated with clinicopathological factors of gastric cancer and inhibits malignancy of gastric cancer cells. Oncol Rep 2014; 31: 2312-2320.
11. Bubnovskaya L, Kovelskaya A, Gumenyuk L, Ganusevich I, Mamontova L, Mikhailenko V et al. Disseminated tumor cells in bone marrow of gastric cancer patients: correlation with tumor hypoxia and clinical relevance. J Oncol 2014; 2014: 582140.
12. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget 2014; 5: 9118-9132.
13. Shibazaki M, Sumi M, Takeda W, Kirihara T, Kurihara T, Sato K et al. Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma. Rinsho Ketsueki 2014; 55: 970-974.
14. Wei S, Wang Y, Chai Q, Fang Q, Zhang Y, Lu Y et al. Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia. Chin Med J (Engl) 2014; 127: 2795-2801.
15. Cai J, Wu G, Tan X, Han Y, Chen C, Li C et al. Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice. PLoS One 2014; 9: e105200.
16. Rondanin R, Simoni D, Romagnoli R, Baruchello R, Marchetti P, Costantini C et al. Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. Bioorg Med Chem Lett 2014; 24: 4568-4574.
17. Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z et al. Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One 2013; 8: e61858.
18. Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res 2013; 319: 1094-1101.
19. Verma M, Karimiani EG, Byers RJ, Rehman S, Westerhoff HV, Day PJ. Mathematical modelling of miRNA mediated BCR.ABL protein regulation in chronic myeloid leukaemia vis-a-vis therapeutic strategies. Integr Biol (Camb) 2013; 5: 543-554.
20. Xishan Z, Xu Z, Lawei Y, Gang L. Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia. Clin Lab 2012; 58: 607-613.
21. Liu Y, Song Y, Ma W, Zheng W, Yin H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res 2013; 37: 349-356.
22. Xu C, Fu H, Gao L, Wang L, Wang W, Li J et al. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene 2014; 33: 44-54.
23. Fei J, Li Y, Zhu X, Luo X. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One 2012; 7: e32834.
24. Lopotová T, Záčková M, Klamová H, Moravcová J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res 2011; 35: 974-977.
25. Pellicano F, Sinclair A, Holyoake TL. In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep 2011; 6: 82-87.
26. Perrotti D, Harb JG. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention. Leuk Lymphoma 2011; 52: 30-44.
27. Hussein K, Büsche G, Muth M, Göhring G, Kreipe H, Bock O. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2011; 90: 307-313.
28. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140: 652-665.
29. Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR et al. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Ann Hematol 2013; 92: 179-183.
30. Cheng A M, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005; 33: 1290-1297.
31. Mansfield JH, Harfe BD, Nissen R, Obenauer J, Srineel J, Chaudhuri A et al. MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet 2004; 36: 1079-1083.
32. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086.
33. Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis 2013; 4: e659.
34. Zhang J, Zhang D, Wu GQ, Feng ZY, Zhu SM. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int 2013; 12: 305-309.
35. Ma D, Tao X, Gao F, Fan C, Wu D. miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 2012; 4: 483-488.
36. Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramírez CM et al. A regulatory role for microRNA 33∗ in controlling lipid metabolism gene expression. Mol Cell Biol 2013; 33: 2339-2352.
37. Cheng C, Li W, Zhang Z, Yoshimura S, Hao Q, Zhang C et al. MicroRNA-144 is regulated by activator protein-1 (AP-1) and decreases expression of Alzheimer disease-related a disintegrin and metalloprotease 10 (ADAM10). J Biol Chem 2013; 288: 13748-13761.
38. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z et al. A combined computational experimental approach predicts human microRNA targets. Genes Dev 2004; 18: 1165-1178.
39. Krek A. Combinatorial microRNA target predictions. Nature Genet 2005; 37: 495-500.
40. Grun D, Wang Y, Langenberger D, Gunsalus KC, Rajewsky N. microRNA Target predictions across seven Drosophila species and comparison to mammalian targets. PLoS Comput Biol 2005; 1: e13.
41. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004; 5: R68.
42. Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32: e188.
43. Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A. MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood 2011; 118: 1899-1902.
44. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 2003; 9: 1274-1281.
45. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 2002; 43: 1289-1295.